Health
Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity
Early responders (15% or more weight loss after 24 weeks) to the higher dose of Wegovy® (semaglutide 7.2 mg) achieved on average 27.7% mean weight loss at week 72 in the STEP UP trial1Participants treated with the higher dose of Wegovy® reached weight loss goals faster as compared to semaglutide 2.4 mg1The majority of the weight loss comes from losing body fat: 84% of weight loss with Wegovy® (semaglutide 2.4 and 7.2 mg) can be attributed to reductions in fat mass, while preserving muscle functi
About this update from Novo Nordisk A/s Class B
[{"type":"image","alt":"Novo Nordisk A/S","displaySize":"","headline":null,"caption":"Novo Nordisk A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":214,"url":"https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GU8RSeYXqJzkiM2VxLxQ7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMA--/https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e","width":300,"height":214},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/GU8RSeYXqJzkiM2VxLxQ7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMA--/https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e","width":300,"height":214}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Early responders (15% or more weight loss after 24 weeks) to the higher dose of Wegovy® (semaglutide 7.2 mg) achieved on average 27.7% mean weight loss at week 72 in the STEP UP trial1","length":184,"tagName":"p"}]},{"val":[{"type":"text","content":"Participants treated with the higher dose of Wegovy® reached weight loss goals faster as compared to semaglutide 2.4 mg1","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"The majority of the weight loss comes from losing body fat: 84% of weight loss with Wegovy® (semaglutide 2.4 and 7.2 mg) can be attributed to reductions in fat mass, while preserving muscle function and improving muscle health2 ","length":227,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":531,"olType":false},{"type":"text","content":"Bagsværd, Denmark, 12 May 2026 – Novo Nordisk is presenting a new sub-analysis from the large clinical trial STEP UP at the European Congress on Obesity (ECO) on 12-15 May in Istanbul, Türkiye, showing that the higher dose of the weight loss drug Wegovy® is highly effective at helping people with obesity lose significant amounts of weight regardless of how quickly their body responds to the treatment1.","length":405,"tagName":"p"},{"type":"text","content":"Moreover, a separate STEP UP sub-analysis presented at ECO shows that most of the weight loss with Wegovy® was coming from body fat, and most of the muscle mass was kept2.","length":171,"tagName":"p"},{"type":"text","content":"The STEP UP trial in people with obesity tested the higher dose of semaglutide (7.2 mg) against the 2.4 mg dose and placeb...